Compare JUBILANT LIFE SCIENCES with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES WOCKHARDT JUBILANT LIFE SCIENCES/
WOCKHARDT
 
P/E (TTM) x 14.9 -55.4 - View Chart
P/BV x 2.8 1.2 226.7% View Chart
Dividend Yield % 0.5 0.0 17,044.5%  

Financials

 JUBILANT LIFE SCIENCES   WOCKHARDT
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
WOCKHARDT
Mar-18
JUBILANT LIFE SCIENCES/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs8981,012 88.7%   
Low Rs618532 116.2%   
Sales per share (Unadj.) Rs572.0355.9 160.7%  
Earnings per share (Unadj.) Rs36.2-60.3 -60.1%  
Cash flow per share (Unadj.) Rs59.5-46.8 -127.3%  
Dividends per share (Unadj.) Rs4.500.01 45,000.0%  
Dividend yield (eoy) %0.60 45,831.4%  
Book value per share (Unadj.) Rs301.9257.8 117.1%  
Shares outstanding (eoy) m159.28110.63 144.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.2 61.1%   
Avg P/E ratio x20.9-12.8 -163.4%  
P/CF ratio (eoy) x12.7-16.5 -77.1%  
Price / Book Value ratio x2.53.0 83.8%  
Dividend payout %12.40 -74,876.5%   
Avg Mkt Cap Rs m120,69485,379 141.4%   
No. of employees `0002.46.3 38.2%   
Total wages/salary Rs m19,2609,371 205.5%   
Avg. sales/employee Rs Th38,120.66,295.0 605.6%   
Avg. wages/employee Rs Th8,058.41,498.3 537.8%   
Avg. net profit/employee Rs Th2,414.3-1,066.3 -226.4%   
INCOME DATA
Net Sales Rs m91,10839,369 231.4%  
Other income Rs m3571,202 29.7%   
Total revenues Rs m91,46640,571 225.4%   
Gross profit Rs m17,39018 95,027.9%  
Depreciation Rs m3,7091,495 248.0%   
Interest Rs m2,1982,555 86.0%   
Profit before tax Rs m11,840-2,830 -418.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,802-3,582 78.2%   
Tax Rs m3,268257 1,271.6%   
Profit after tax Rs m5,770-6,669 -86.5%  
Gross profit margin %19.10 41,062.7%  
Effective tax rate %27.6-9.1 -303.9%   
Net profit margin %6.3-16.9 -37.4%  
BALANCE SHEET DATA
Current assets Rs m45,84833,796 135.7%   
Current liabilities Rs m20,89726,917 77.6%   
Net working cap to sales %27.417.5 156.7%  
Current ratio x2.21.3 174.7%  
Inventory Days Days5779 71.6%  
Debtors Days Days5189 57.1%  
Net fixed assets Rs m65,49839,664 165.1%   
Share capital Rs m159553 28.8%   
"Free" reserves Rs m47,93027,968 171.4%   
Net worth Rs m48,08928,522 168.6%   
Long term debt Rs m42,42921,731 195.2%   
Total assets Rs m114,68581,620 140.5%  
Interest coverage x6.4-0.1 -5,940.0%   
Debt to equity ratio x0.90.8 115.8%  
Sales to assets ratio x0.80.5 164.7%   
Return on assets %6.9-5.0 -137.9%  
Return on equity %12.0-23.4 -51.3%  
Return on capital %12.4-7.7 -161.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,4229,807 126.7%   
Fx outflow Rs m17,2271,789 963.2%   
Net fx Rs m-4,8058,019 -59.9%   
CASH FLOW
From Operations Rs m11,215684 1,638.7%  
From Investments Rs m-10,1186,302 -160.5%  
From Financial Activity Rs m6,574-7,695 -85.4%  
Net Cashflow Rs m7,612-664 -1,146.4%  

Share Holding

Indian Promoters % 45.6 74.5 61.2%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 2.3 378.3%  
FIIs % 21.2 7.7 275.3%  
ADR/GDR % 0.0 0.1 -  
Free float % 21.1 15.4 137.0%  
Shareholders   23,815 67,757 35.1%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   SANOFI INDIA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  CIPLA  TORRENT PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 11, 2020 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS